Cardiol Therapeutics (CRTPF) Stock Price, News & Analysis

Company Overview

Cardiol Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory heart diseases. The company’s proprietary drug platform leverages the anti-inflammatory and immunomodulatory properties of cannabinoids to address conditions such as acute myocarditis and chronic heart failure. Cardiol’s lead candidate, CT-001, is an injectable formulation of cannabidiol designed to reduce cardiac inflammation and limit tissue damage following injury.

In addition to CT-001, Cardiol is advancing a second asset, CT-201, which is being investigated for the prevention of myocardial ischemia-reperfusion injury. Both programs are supported by an exclusive global license to novel cannabinoid formulations developed through academic collaborations. Preclinical data have demonstrated the potential of these candidates to modulate the immune response in cardiac tissue, and the company has initiated early-stage clinical trials to assess safety and efficacy in patients.

Founded in 2016 and headquartered in Toronto, Ontario, Cardiol Therapeutics operates research and development activities in North America, with clinical trial sites in both Canada and the United States. The company is committed to exploring the role of cannabinoids beyond traditional indications by focusing on high-unmet-need cardiovascular conditions. Its research strategy includes partnerships with leading academic institutions and contract research organizations to advance its pipeline efficiently.

Cardiol’s management team brings together expertise in pharmaceutical development, regulatory affairs and clinical research. Guided by a board of directors with backgrounds spanning biotechnology, cardiology and commercial operations, the company aims to translate its novel cannabinoid technology into safe and effective treatments for patients with inflammatory cardiac diseases.

Key Stats

• Today's Range: $1.29 to $1.37
• 50-Day Range: $1.06 to $1.54
• 52-Week Range: $1.48 to $4.19
• Volume: 133,111 shs
• Average Volume: 67,097 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CRTPF Stock Analysis - Frequently Asked Questions

How have CRTPF shares performed this year?

Cardiol Therapeutics' stock was trading at $1.28 at the beginning of the year. Since then, CRTPF stock has increased by 3.9% and is now trading at $1.33.

How do I buy shares of Cardiol Therapeutics?

Shares of CRTPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:CRTPF
• CIK: N/A
• Web: www.cardiolrx.com
• Phone: (289) 910-0850
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A